The Implication of ctDNA in the Recurrence Surveillance of Stage II and III Colorectal Cancer
The Implication of Plasma Circulating Tumor DNA (ctDNA) in the Recurrence Surveillance of Stage II and III Colorectal Cancer: a Prospective Study
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University
This observational or N/A phase trial investigates Colorectal Cancer and Surveillance and is currently ongoing. Sixth Affiliated Hospital, Sun Yat-sen University leads this study, which shows 6 recorded versions since 2018 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Jan 2021 [monthly]
Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Recruiting
Phase: NA → None
▶ Show 1 earlier version
-
Feb 2018 — Apr 2018 [monthly]
Recruiting NA
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sixth Affiliated Hospital, Sun Yat-sen University
For direct contact, visit the study record on ClinicalTrials.gov .